403 related articles for article (PubMed ID: 32776391)
21. Prognostic values of the integrated model incorporating the volume of metastatic regional cervical lymph node and pretreatment serum Epstein-Barr virus DNA copy number in predicting distant metastasis in patients with N1 nasopharyngeal carcinoma.
Yao JJ; Zhou GQ; Wang YQ; Wang SY; Zhang WJ; Jin YN; Zhang F; Li L; Liu LZ; Cheng ZB; Ma J; Qi ZY; Sun Y
Chin J Cancer; 2017 Dec; 36(1):98. PubMed ID: 29284539
[TBL] [Abstract][Full Text] [Related]
22. Comparing three induction chemotherapy regimens for patients with locoregionally advanced nasopharyngeal carcinoma based on TNM stage and plasma Epstein-Barr virus DNA level.
Liu SL; Sun XS; Xie HJ; Chen QY; Lin HX; Liang H; Liang YJ; Li XY; Yan JJ; Lin C; Yang ZC; Guo SS; Liu LT; Tang QN; Du YY; Tang LQ; Guo L; Mai HQ
BMC Cancer; 2020 Feb; 20(1):89. PubMed ID: 32013967
[TBL] [Abstract][Full Text] [Related]
23. Survival analysis of patients with advanced-stage nasopharyngeal carcinoma according to the Epstein-Barr virus status.
Peng H; Chen L; Zhang Y; Guo R; Li WF; Mao YP; Tan LL; Sun Y; Zhang F; Liu LZ; Tian L; Lin AH; Ma J
Oncotarget; 2016 Apr; 7(17):24208-16. PubMed ID: 27008701
[TBL] [Abstract][Full Text] [Related]
24. Role of sequential chemoradiotherapy in stage II and low-risk stage III-IV nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy: A propensity score-matched analysis.
Xu C; Sun R; Tang LL; Chen L; Li WF; Mao YP; Zhou GQ; Guo R; Lin AH; Sun Y; Ma J; Hu WH
Oral Oncol; 2018 Mar; 78():37-45. PubMed ID: 29496056
[TBL] [Abstract][Full Text] [Related]
25. A novel scoring model to predict benefit of additional induction chemotherapy to concurrent chemoradiotherapy in stage II-IVa nasopharyngeal carcinoma.
Peng L; Chen YP; Xu C; Tang LL; Chen L; Lin AH; Liu X; Sun Y; Ma J
Oral Oncol; 2018 Nov; 86():258-265. PubMed ID: 30409310
[TBL] [Abstract][Full Text] [Related]
26. The efficacy and safety of docetaxel, cisplatin and fluorouracil (TPF)-based induction chemotherapy followed by concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a meta-analysis.
Zhou R; Zhu J; Chen X; Liu Y; Wang Y; Zhang T
Clin Transl Oncol; 2020 Mar; 22(3):429-439. PubMed ID: 31165410
[TBL] [Abstract][Full Text] [Related]
27. Individualized concurrent chemotherapy by pretreatment plasma Epstein-Barr viral DNA in II-III stage nasopharyngeal carcinoma: A propensity score matching analysis using a large cohort.
Sun XS; Chen WH; Liu SL; Liang YJ; Chen QY; Guo SS; Wen YF; Liu LT; Xie HJ; Tang QN; Li XY; Yan JJ; Mai HQ; Tang LQ
Cancer Med; 2019 Aug; 8(9):4214-4225. PubMed ID: 31210417
[TBL] [Abstract][Full Text] [Related]
28. Epstein-Barr virus DNA change level combined with tumor volume reduction ratio after inductive chemotherapy as a better prognostic predictor in locally advanced nasopharyngeal carcinoma.
Xiang ZZ; He T; Zeng YY; Liu F; Shao BF; Yang T; Ma JC; Wang XR; Yu ST; Liu L
Cancer Med; 2023 Jan; 12(2):1102-1113. PubMed ID: 35852473
[TBL] [Abstract][Full Text] [Related]
29. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study.
Qiu WZ; Huang PY; Shi JL; Xia HQ; Zhao C; Cao KJ
Chin J Cancer; 2016 Jan; 35():2. PubMed ID: 26739148
[TBL] [Abstract][Full Text] [Related]
30. Combining plasma Epstein-Barr virus DNA and nodal maximal standard uptake values of 18F-fluoro-2-deoxy-D-glucose positron emission tomography improved prognostic stratification to predict distant metastasis for locoregionally advanced nasopharyngeal carcinoma.
Chen WH; Tang LQ; Zhang L; Chen QY; Guo SS; Liu LT; Fan W; Zhang X; Guo L; Zhao C; Cao KJ; Qian CN; Guo X; Xie D; Zeng MS; Mai HQ
Oncotarget; 2015 Nov; 6(35):38296-307. PubMed ID: 26512922
[TBL] [Abstract][Full Text] [Related]
31. Identifying optimal candidates for induction chemotherapy among stage II-IVa nasopharyngeal carcinoma based on pretreatment Epstein-Barr virus DNA and nodal maximal standard uptake values of [
Xie HJ; Yu YF; Sun XS; Jia GD; Luo DH; Sun R; Liu LT; Guo SS; Liu SL; Chen QY; Tang LQ; Mai HQ
Cancer Med; 2020 Dec; 9(23):8852-8863. PubMed ID: 33034945
[TBL] [Abstract][Full Text] [Related]
32. Combining tumor response and personalized risk assessment: Potential for adaptation of concurrent chemotherapy in locoregionally advanced nasopharyngeal carcinoma in the intensity-modulated radiotherapy era.
Luo WJ; Zou WQ; Liang SB; Chen L; Zhou GQ; Peng H; Li WF; Liu X; Sun Y; Lin AH; Ma J; Mao YP
Radiother Oncol; 2021 Feb; 155():56-64. PubMed ID: 33039423
[TBL] [Abstract][Full Text] [Related]
33. Establishing and applying nomograms based on the 8th edition of the UICC/AJCC staging system to select patients with nasopharyngeal carcinoma who benefit from induction chemotherapy plus concurrent chemoradiotherapy.
Xu C; Chen YP; Liu X; Li WF; Chen L; Mao YP; Zhang Y; Guo R; Zhou GQ; Tang LL; Lin AH; Sun Y; Ma J
Oral Oncol; 2017 Jun; 69():99-107. PubMed ID: 28559028
[TBL] [Abstract][Full Text] [Related]
34. A deep learning-based radiomic nomogram for prognosis and treatment decision in advanced nasopharyngeal carcinoma: A multicentre study.
Zhong L; Dong D; Fang X; Zhang F; Zhang N; Zhang L; Fang M; Jiang W; Liang S; Li C; Liu Y; Zhao X; Cao R; Shan H; Hu Z; Ma J; Tang L; Tian J
EBioMedicine; 2021 Aug; 70():103522. PubMed ID: 34391094
[TBL] [Abstract][Full Text] [Related]
35. Effect of induction chemotherapy with cisplatin, fluorouracil, with or without taxane on locoregionally advanced nasopharyngeal carcinoma: a retrospective, propensity score-matched analysis.
Liu GY; Lv X; Wu YS; Mao MJ; Ye YF; Yu YH; Liang H; Yang J; Ke LR; Qiu WZ; Huang XJ; Li WZ; Guo X; Xiang YQ; Xia WX
Cancer Commun (Lond); 2018 May; 38(1):21. PubMed ID: 29764487
[TBL] [Abstract][Full Text] [Related]
36. Integrative Scoring System for Survival Prediction in Patients With Locally Advanced Nasopharyngeal Carcinoma: A Retrospective Multicenter Study.
Zhang B; Luo C; Zhang X; Hou J; Liu S; Gao M; Zhang L; Jin Z; Chen Q; Yu X; Zhang S
JCO Clin Cancer Inform; 2023 Feb; 7():e2200015. PubMed ID: 36877918
[TBL] [Abstract][Full Text] [Related]
37. Beneficial effects of anti-EGFR agents, Cetuximab or Nimotuzumab, in combination with concurrent chemoradiotherapy in advanced nasopharyngeal carcinoma.
Lin M; You R; Liu YP; Zhang YN; Zhang HJ; Zou X; Yang Q; Li CF; Hua YJ; Yu T; Cao JY; Li JB; Mo HY; Guo L; Lin AH; Sun Y; Qian CN; Ma J; Mai HQ; Chen MY
Oral Oncol; 2018 May; 80():1-8. PubMed ID: 29706183
[TBL] [Abstract][Full Text] [Related]
38. Concurrent chemoradiotherapy with or without cetuximab for stage II to IVb nasopharyngeal carcinoma: a case-control study.
Li Y; Chen QY; Tang LQ; Liu LT; Guo SS; Guo L; Mo HY; Chen MY; Guo X; Cao KJ; Qian CN; Zeng MS; Bei JX; Shao JY; Sun Y; Tan J; Chen S; Ma J; Zhao C; Mai HQ
BMC Cancer; 2017 Aug; 17(1):567. PubMed ID: 28836950
[TBL] [Abstract][Full Text] [Related]
39. MRI-Based Metastatic Nodal Number and Associated Nomogram Improve Stratification of Nasopharyngeal Carcinoma Patients: Potential Indications for Individual Induction Chemotherapy.
Zhao Q; Dong A; Cui C; Ou Q; Ruan G; Zhou J; Tian L; Liu L; Ma H; Li H
J Magn Reson Imaging; 2023 Jun; 57(6):1790-1802. PubMed ID: 36169976
[TBL] [Abstract][Full Text] [Related]
40. Baseline Low Prognostic Nutritional Index Predicts Poor Survival in Locally Advanced Nasopharyngeal Carcinomas Treated With Radical Concurrent Chemoradiotherapy.
Topkan E; Yucel Ekici N; Ozdemir Y; Besen AA; Mertsoylu H; Sezer A; Selek U
Ear Nose Throat J; 2021 Feb; 100(2):NP69-NP76. PubMed ID: 31184210
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
